Single-drug treatments for chronic hepatitis B: Summarising current information by network meta-analysis

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 1, 2011, Pages 105-107

  Messori, A ^a   Del Santo, F ^a   Maratea, D ^a   Trippoli, S ^a  

^a ESTAV   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

CLINICAL EFFECTIVENESS; DRUG CHOICE; HEPATITIS B; HUMAN; LETTER; METHODOLOGY; MONOTHERAPY; NETWORK META ANALYSIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79958129557     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04689.x     Document Type: Letter

References (4)

1. Rijckborst V, Sonneveld MJ, Janssen HLA,. Review article: chronic hepatitis B-anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther 2011; 33: 501-13.
2. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
3. Caldwell DM, Ades AE, Higgins JPT,. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897-900. (Pubitemid 41502718)
4. Messori A, Del Santo F, Maratea D,. First-line treatments for hepatitis C. Aliment Pharmacol Ther 2011; 33: 1383-5.